Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 37-5

Table of Contents

von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Hereditary Renal Cell Carcinoma Syndromes
The Role of the Pathologist in Renal Cell Carcinoma Management
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Surgical Management of Localized Disease and Small Renal Masses
Role of Surgery in Metastatic Renal Cell Carcinoma
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Role of Radiation in Treatment of Renal Cell Carcinoma
Prognostic Models in Metastatic Renal Cell Carcinoma
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Renal Cell Carcinoma of Variant Histology: Biology and Therapies
Toxicity Management of Systemic Kidney Cancer Therapies
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes

Authors

Bradley A. Mcgregor Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. Toni K. Choueiri Jerome and Nancy Kohlberg Professor, Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncology, Dana-Farber Cancer Institute, Director, Genitourinary (GU) Oncology Disease Center,Dana-Farber Cancer Institute.